Drug discovery and biology

• Demis Hassabis: CEO; also heads Google DeepMind, from which Isomorphic was spun off (Reuters (via Yahoo Finance), Jeffrey Dastin and Deborah Sophia, Jan 20, 2026)

• Mar 2025, First external round: $600 million. Investors named: Thrive Capital (lead) (Reuters (via Yahoo Finance), Jeffrey Dastin and Deborah Sophia, Jan 20, 2026)
• May 12, 2026, Series B: $2.1 billion. Investors named: Thrive Capital (lead), Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund (Isomorphic Labs press release (company), May 12, 2026)
• Oct 8, 2026, New round (early talks; not confirmed): not disclosed, valued at $40 billion to $50 billion (reported) (SiliconANGLE, citing Bloomberg, Oct 8, 2026)

• Peer-reviewed: 'Accurate structure prediction of biomolecular interactions with AlphaFold 3', Nature 630, 493-500, doi:10.1038/s41586-024-07487-w (joint DeepMind/Isomorphic work). (Nature 630, 493-500 (record via RePEc/IDEAS), Jun 2024)

Alphabet-backed spinoff of Google DeepMind (Alphabet invests directly), so it sits at the edge of 'not a big-tech division'. No clinical trial registry entry was found; in Jan 2026 Hassabis said it "expects to have its first clinical trials by the end of 2026" after earlier targeting end-2025 (Reuters). Partnerships with Eli Lilly and Novartis (2024) and Johnson & Johnson (Jan 2026) per SiliconANGLE. No valuation for the May 2026 round was found in a trusted source.

• Joshua Meier: CEO; researcher at OpenAI during GPT-1 and GPT-2, co-led ESM1 at Meta, then chief AI officer at Absci (GEN (Genetic Engineering & Biotechnology News), Dec 16, 2025)
• Matthew McPartlon: previously tech lead for de novo antibody design modeling at Absci (GEN (Genetic Engineering & Biotechnology News), Dec 16, 2025)
• Jacques Boitreaud: previously led AI at Aqemia (GEN (Genetic Engineering & Biotechnology News), Dec 16, 2025)
• Jack Dent: president; previously led product and engineering teams at Stripe (GEN (Genetic Engineering & Biotechnology News), Dec 16, 2025)

• Dec 16, 2025, Series B: $130 million, valued at $1.3 billion. Investors named: Oak HC/FT (co-lead), General Catalyst (co-lead), Thrive Capital, OpenAI, Emerson Collective (GEN (Genetic Engineering & Biotechnology News), Dec 16, 2025)
• Jul 14, 2026, Series C: $400 million, valued at $3.8 billion. Investors named: Index Ventures (lead), Kleiner Perkins, Sequoia Capital, Dimension, Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst (SiliconANGLE, Kyt Dotson, Jul 14, 2026)

Chai-2 results (16% binding rate across 52 targets) are company-reported in a technical report and bioRxiv preprint, not peer-reviewed as of the pages fetched. No clinical trial registry entry; Chai licenses models rather than running its own clinical pipeline on the pages fetched. Founding year inferred from GEN saying Meier co-founded it 'last year' (article dated Dec 2025). The Pharma Letter (2026-07-15) confirms amount, valuation and lead.

• Ali Madani: AI researcher with a UC Berkeley doctorate; worked at Salesforce, where the ProGen project launched; lead author of a Nature Biotechnology paper on ProGen (Forbes, Amy Feldman, Nov 19, 2025)
• Alexander Meeske: University of Washington lab head (Forbes says he teamed up with Madani to build the company) (Forbes, Amy Feldman, Nov 19, 2025)

• Nov 19, 2025, Not specified: $106 million (total raised $150 million), valued at approaching $1 billion. Investors named: Bezos Expeditions (co-lead), Altimeter Capital (co-lead) (Forbes, Amy Feldman, Nov 19, 2025)

A Bloomberg headline reposted by Profluent (2026-04-28) says a Lilly deal is worth up to $2.25 billion; the Bloomberg article itself could not be fetched, so terms are unverified. OpenCRISPR-1 results are from a preprint; no peer-reviewed version was found on pages fetched. No own clinical pipeline found.

• Marc Tessier-Lavigne: CEO (named as CEO, not founder); former president of Stanford and Rockefeller universities; former Genentech research SVP; Denali Therapeutics co-founder (Bloomberg News, Apr 23, 2024)

• Apr 23, 2024, Launch financing (capital commitments): $1 billion. Investors named: ARCH Venture Partners (incubator), Foresite Labs (incubator), Sequoia Capital, Lightspeed Venture Partners, F-Prime, NEA, Lux Capital, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy (Bloomberg News, Apr 23, 2024)

No clinical trial registry entry or peer-reviewed paper by Xaira was found; programs are preclinical (XA-4 'has entered lead optimization'). Its homepage quote is cut off at the word 'power' (it continues to name AI). Later funding was not verified.

• Simon Kohl: former DeepMind research scientist on the core AlphaFold2 team; co-led DeepMind's protein design team and set up its wet lab at the Francis Crick Institute (TechCrunch, Paul Sawers, Feb 12, 2025)

• Feb 12, 2025, Seed ($10M, previously unannounced) and Series A ($40M): $50 million total. Investors named: Radical Ventures (Series A co-lead), Sofinnova Partners (Series A co-lead), Flying Fish, Isomer, 8VC, Kindred Capital, Pillar VC, Jeff Dean, Aidan Gomez, Mati Staniszewski (TechCrunch, Paul Sawers, Feb 12, 2025)

Incorporated in London in mid-2023 (TechCrunch); also has a San Francisco wet lab. No valuation found. Beta results at UC Davis, LMU University Hospital and TGen are reported by the company, not by those groups on pages fetched. No later funding found.

• Stef van Grieken: CEO and co-founder (no background given on page) (Cradle (company blog), Nov 17, 2022)

• Nov 17, 2022, Seed: €5.5 million ($5.4m). Investors named: Index Ventures (co-lead), Kindred Capital (co-lead), Feike Sijbesma, Emily Leproust (Cradle (company blog), Nov 17, 2022)
• Nov 28, 2023, Series A: $24 million (Cradle blog index (company))
• Nov 26, 2024, Series B: $73 million. Investors named: IVP (lead), Index Ventures, Kindred Capital (Cradle (company blog), Nov 26, 2024)

• Per Cradle, its design placed second on affinity (8.69 pM) among 23 ranked organizations in the blind, third-party-assayed AIntibody challenge, with results published in Nature Biotechnology (2026; paper page could not be fetched). (Cradle (company blog), describing the AIntibody challenge results, Oct 12, 2026)

Founded before or in 2022 (exited stealth 2022-11-17); founding year not stated, so it may sit near the 2020 cutoff. Offices in Delft (Netherlands) and Zurich; site says 'Built in Amsterdam & Zurich'. Series B post names Novo Nordisk, J&J Innovative Medicine, Novonesis and Grifols as customers. Its tools engineer proteins for customers; no own clinical pipeline, so no registry entry applies. No 2025-2026 funding round found.

• Jakob Uszkoreit: co-founder and CEO; one of eight authors of the 2017 Transformer paper while a software engineer at Google (Crazy Stupid Tech (newsletter), Jan 12, 2025)
• Rhiju Das: Stanford biochemistry professor (Crazy Stupid Tech (newsletter), Jan 12, 2025)

• Jan 12, 2025, Two early rounds (cumulative, as reported): about $120 million committed. Investors named: Andreessen Horowitz, Obvious Ventures, Section 32, Nvidia (Crazy Stupid Tech (newsletter), Jan 12, 2025)

Funding figure comes from a tech newsletter (Crazy Stupid Tech), not a listed trusted outlet, and has no round dates; the company site names backers but no amounts. No product, peer-reviewed paper or trial registry entry found. Offices in Palo Alto, Berlin and Zurich.

• Jean-Philippe Vert: co-founder and CEO; Chief R&D Officer of Owkin and former Research Lead at Google Brain (as of Feb 2024) (Bioptimus (company), Feb 20, 2024)

• Feb 20, 2024, Seed: $35 million. Investors named: Sofinnova Partners (lead), Bpifrance Large Venture, Frst, Cathay Innovation, Headline, Hummingbird, NJF Capital, Owkin, Top Harvest Capital, Xavier Niel (Bioptimus (company), Feb 20, 2024)
• Jan 14, 2025, Not named (extension; total $76 million): $41 million. Investors named: Cathay Innovation (lead), Sofinnova Partners, Bpifrance Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Sunrise, Emmanuel Cassimatis, Thomas Wolf (Bioptimus (company), Jan 14, 2025)

A pathology and multimodal biology model company rather than a drug developer, so no trial registry applies. Emerged from stealth 2024-02-20; founding year not stated. Company says H-Optimus-0 'consistently meets the performance or outperforms existing models' (company claim; no scores given). No 2025-2026 round beyond Jan 2025 found.